CB1a, a rationally designed anticancer peptide, showed selective tumor cell killing through membrane disruption with characterized 3D structure — demonstrating successful de novo anticancer peptide engineering.
Key findingCB1a, a rationally designed anticancer peptide, showed selective tumor cell killing through membrane disruption with characterized 3D structure — demo
What the researchers found
CB1a, a rationally designed anticancer peptide, showed selective tumor cell killing through membrane disruption with characterized 3D structure — demonstrating successful de novo anticancer peptide engineering.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2009.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Structure and function of a custom anticancer peptide, CB1a.
Peptides, 30(5), 839-48
Citation
Wu, Jiun-Ming; Jan, Pey-Shynan; Yu, Hui-Chen; Haung, Hsu-Yuang; Fang, Huey-Jen; Chang, Yuan-I; Cheng, Jya-Wei; Chen, Hueih Min. (2009). Structure and function of a custom anticancer peptide, CB1a.. Peptides, 30(5), 839-48. https://doi.org/10.1016/j.peptides.2009.02.004